CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
2.650
-0.140 (-5.02%)
Dec 20, 2024, 4:00 PM EST - Market closed
CASI Pharmaceuticals Revenue
CASI Pharmaceuticals had revenue of $7.79M in the quarter ending September 30, 2024, a decrease of -11.82%. This brings the company's revenue in the last twelve months to $22.06M, down -47.82% year-over-year. In the year 2023, CASI Pharmaceuticals had annual revenue of $33.88M, down -21.41%.
Revenue (ttm)
$22.06M
Revenue Growth
-47.82%
P/S Ratio
1.67
Revenue / Employee
$125,313
Employees
176
Market Cap
39.88M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 33.88M | -9.23M | -21.41% |
Dec 31, 2022 | 43.11M | 12.94M | 42.89% |
Dec 31, 2021 | 30.17M | 15.03M | 99.25% |
Dec 31, 2020 | 15.14M | 11.01M | 266.52% |
Dec 31, 2019 | 4.13M | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ImmuCell | 23.84M |
Barinthus Biotherapeutics | 14.97M |
Exicure | 500.00K |
Nexalin Technology | 162.08K |
Daxor | 154.21K |
Q32 Bio | -14.66M |
CASI News
- 5 weeks ago - CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - Accesswire
- 2 months ago - CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Accesswire
- 3 months ago - CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - PRNewsWire
- 4 months ago - CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - PRNewsWire
- 5 months ago - CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - PRNewsWire
- 5 months ago - CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP - PRNewsWire
- 6 months ago - CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company - PRNewsWire
- 6 months ago - CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He - PRNewsWire